TECX news

Latest 2 stories · newest Sep 29, 2026

TECX

Tectonic Announces Positive Phase 1 Safety Data for TX2100

Tectonic reported favorable safety and tolerability results for its candidate TX2100 at the APJ receptor, triggering its Fast Track designation and allowing progression into Phase 1b trials.

Regulatory Sep 29, 2026 sentiment +0.80 SEC filing ↗

TECX

Tectonic completes enrollment of 191 patients in TX45 Phase 2 PH-HFpEF trial

Tectonic Therapeutic completed enrollment in its APEX Phase 2 clinical trial testing TX45 in pulmonary hypertension patients, with 72% of participants in the targeted severe disease subtype. Topline results are expected in early Q1 2027, a key catalyst for the clinical-stage biotech company.

Regulatory Jun 10, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same TECX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/TECX/newsSTART FREE